P4HB and food allergy: Furthermore, treatment with PACMA-31, an orally bioactive, irreversible inhibitor of PDI suppressed mast cell responses both in cell culture and during the development of food allergy, suggesting that therapeutic targeting of PDI in allergic patients may prove to be of benefit.